中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
2期
22-24
,共3页
重组人血小板生成素%白血病%淋巴瘤%血小板减少
重組人血小闆生成素%白血病%淋巴瘤%血小闆減少
중조인혈소판생성소%백혈병%림파류%혈소판감소
Recombinant human thrombopoietin%Leukemia%Lymphoma%Thrombocytopenia
目的 评价国产重组人血小板生成素(rhTPO)对恶性血液病患者化疗后血小板减少的临床疗效和安全性.方法 化疗后血小板≤20×109/L的12例白血病和淋巴瘤患者接受方案和剂量相同的2个周期化疗,第1周期作为自身对照,第2周期当血小板≤50×109/L时皮下注射rhTPO 15 000 U/d为用药组,连续用药8～14 d(血小扳升至≥75×109/L停用),监测血及尿常规、肝肾功能、凝血功能.结果 用药组血小板最低平均值(11±4)×109/L与对照组(9.4±2.9)×109/L比较,差异无统计学意义(P＞0.05),血小板＜20×109/L的持续天数用药组为(7.6±2.0)d,和对照组[(8.7±2.2)d]比较差异有统计学意义(P＜0.05).血小板恢复最高值分别为(253±86)×109/L和(178±53)×109/L,差异有统计学意义(P＜0.05).血小板输注量用药组为(21.7±3.9)U,对照组为(24.2±5.1)U,差异无统计学意义(P＞0.05).用药组未见严重不良反应.结论 rhTPO可减少恶性血液病化疗后血小板降低的持续时间,提高血小板恢复后水平,且具有良好的安全性.
目的 評價國產重組人血小闆生成素(rhTPO)對噁性血液病患者化療後血小闆減少的臨床療效和安全性.方法 化療後血小闆≤20×109/L的12例白血病和淋巴瘤患者接受方案和劑量相同的2箇週期化療,第1週期作為自身對照,第2週期噹血小闆≤50×109/L時皮下註射rhTPO 15 000 U/d為用藥組,連續用藥8～14 d(血小扳升至≥75×109/L停用),鑑測血及尿常規、肝腎功能、凝血功能.結果 用藥組血小闆最低平均值(11±4)×109/L與對照組(9.4±2.9)×109/L比較,差異無統計學意義(P＞0.05),血小闆＜20×109/L的持續天數用藥組為(7.6±2.0)d,和對照組[(8.7±2.2)d]比較差異有統計學意義(P＜0.05).血小闆恢複最高值分彆為(253±86)×109/L和(178±53)×109/L,差異有統計學意義(P＜0.05).血小闆輸註量用藥組為(21.7±3.9)U,對照組為(24.2±5.1)U,差異無統計學意義(P＞0.05).用藥組未見嚴重不良反應.結論 rhTPO可減少噁性血液病化療後血小闆降低的持續時間,提高血小闆恢複後水平,且具有良好的安全性.
목적 평개국산중조인혈소판생성소(rhTPO)대악성혈액병환자화료후혈소판감소적림상료효화안전성.방법 화료후혈소판≤20×109/L적12례백혈병화림파류환자접수방안화제량상동적2개주기화료,제1주기작위자신대조,제2주기당혈소판≤50×109/L시피하주사rhTPO 15 000 U/d위용약조,련속용약8～14 d(혈소반승지≥75×109/L정용),감측혈급뇨상규、간신공능、응혈공능.결과 용약조혈소판최저평균치(11±4)×109/L여대조조(9.4±2.9)×109/L비교,차이무통계학의의(P＞0.05),혈소판＜20×109/L적지속천수용약조위(7.6±2.0)d,화대조조[(8.7±2.2)d]비교차이유통계학의의(P＜0.05).혈소판회복최고치분별위(253±86)×109/L화(178±53)×109/L,차이유통계학의의(P＜0.05).혈소판수주량용약조위(21.7±3.9)U,대조조위(24.2±5.1)U,차이무통계학의의(P＞0.05).용약조미견엄중불량반응.결론 rhTPO가감소악성혈액병화료후혈소판강저적지속시간,제고혈소판회복후수평,차구유량호적안전성.
Objective To evaluate the safety and effectiveness of rhTPO on the treatment of chemotherapy - induced thrombocytopenia in patients with hematological malignancies. Methods Twelve leukemia and lymphoma patients with platelet count ≤20 × 109/L after chemotherapy were enrolled in the current study. They received two courses of chemotherapy with identical regimen and dosage. The first course was used as self - control. In the second course, rhTPO was subcutaneously administered at a dosage of 15 000 U/d for 8 - 14 days (until the platelet count ≥75× 109/L) when platelet count ≤50 × 109/L. Laboratory tests included blood routine and urine routine, serum biochemisty, blood coagulation tests. Results The mean minimal platelet count was( 11 ±4) × 109/L in the treatment goup versus(9.4 ±2.9) ×109/L in the control group, the difference was no significant (P ＞0.05). The duration of patients with platelet count ＜20 × 10 9/L was(7. 6 ±2. 0)d in the treatment group and(8. 7 ± 2. 2)d in the control group, the difference was significant (P ＜0.05). The mean maximal platelet count in patients' recovery period was(253 ±86) × 109/L and( 178 ±53) × 109/L respectively, the difference was significant (P ＜0.05). Platelet transfusion was(21.7 ±3.9)U in the treatment group and(24.2 ± 5.1)U in the control group, the difference was nor significant (P ＞0. 05 ). No severe side - effect was observed in the treatment group. Conclusions rhTPO could reduce the duration of chemotherapy - induced thrombocytopenia in patients with hematological malignancies and elevate the platelet count and without severe side - effect.
